In recognition of Melanoma Awareness Month, the Melanoma Research Alliance has announced funding for 26 research awards, totaling $10.9 million. These grant awards are made possible through the significant contributions of individuals, families, institutions, and corporate allies. The 26 awards will support research at 23 institutions in 5 countries.
“As many people begin to focus on how to safely reopen our communities, [the Melanoma Research Alliance] is committed to a continued and robust pipeline of research that can eliminate pain and suffering due to melanoma,” said Debra Black, Cofounder and Board Chair.
In addition to providing an influx of funding as researchers return to their labs, these research awards support innovative ideas with the potential to rapidly improve outcomes for patients with melanoma. The expansive project goals include research aimed at validating the use of artificial intelligence to improve early melanoma diagnosis; exploring chimeric antigen receptor T-cell therapy as a future melanoma treatment option; and evaluating how best to combine surgery, radiotherapy, and systemic treatments for metastatic disease, including neoadjuvant approaches.
Marc Hurlbert, PhD
“This year, for the first time ever, we estimate that more than 100,000 people in the United States will be diagnosed with invasive melanoma,” commented Chief Science Officer of the Melanoma Research Alliance, Marc Hurlbert, PhD. “While our efforts over the past decade have reduced melanoma mortality rates, we still must continue to advance research needed to improve outcomes for all patients facing melanoma.”
To see all of the award recipients, visit the Melanoma Research Alliance at https://www.curemelanoma.org.